Massachusetts Wealth Management Purchases 230 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Massachusetts Wealth Management raised its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,414 shares of the company’s stock after buying an additional 230 shares during the quarter. Massachusetts Wealth Management owned about 0.46% of Invesco Biotechnology & Genome ETF worth $1,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Howe & Rusling Inc. acquired a new stake in Invesco Biotechnology & Genome ETF in the third quarter valued at about $31,000. Carnegie Investment Counsel bought a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter worth about $204,000. Jane Street Group LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $295,000. Creative Financial Designs Inc. ADV grew its holdings in shares of Invesco Biotechnology & Genome ETF by 5.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after purchasing an additional 299 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in Invesco Biotechnology & Genome ETF by 64.1% during the 3rd quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after purchasing an additional 2,774 shares in the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of Invesco Biotechnology & Genome ETF stock opened at $69.05 on Wednesday. The company’s 50 day moving average price is $68.64 and its two-hundred day moving average price is $69.21. The firm has a market capitalization of $278.96 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a fifty-two week low of $59.32 and a fifty-two week high of $72.84.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.